title: Clinical responses to the combination of estradiol and drospirenone in symptomatic postmenopausal Thai women.
abstract: OBJECTIVE
  To investigate the efficacy and tolerability of the oral hormone replacement therapy (HRT) containing 1 mg estradiol (E2) plus 2 mg drospirenone (DRSP) in Thai women with postmenopausal symptoms.
  
  
  METHODS
  Fifty-five Thai women with postmenopausal symptoms participated in this multicenter, open-label, non-comparative Phase IV study. The primary endpoint was the reduction of hot flushes after 12 weeks of treatment. Secondary endpoints included changes infrequency and intensity of menopausal symptoms as well as safety assessments after 4, 8, and 12 weeks of treatment.
  
  
  RESULTS
  Treatment with 1 mg E2 plus 2 mg DRSP reduced the frequency of hot flushes in 94.6% of women at the end of the 12-week treatment period. In 60% of women, the frequency of hot flushes was reduced to 10% or less, compared to baseline findings and 49.1% of women had no remaining hot flushes. Other postmenopausal symptoms such as vaginal dryness, urinary incontinence, dysuria, and dyspareunia improved The most common adverse events were vaginal bleeding or spotting and breast tenderness.
  
  
  CONCLUSIONS
  The oral HRT of 1 mg E2 plus 2 mg DRSP was effective and well tolerated by Thai women suffering from postmenopausal symptoms.
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. sukanya.c@chula.ac.th
authors.forename: Sukanya
authors.initials: S
authors.lastname: Chaikittisilpa
authors.forename: Surasak
authors.initials: S
authors.lastname: Angsuwathana
authors.forename: Somsak
authors.initials: S
authors.lastname: Chaovisitsaree
authors.forename: Mayuree
authors.initials: M
authors.lastname: Jirapinyo
authors.forename: Kittisak
authors.initials: K
authors.lastname: Wilawan
authors.forename: Krasean
authors.initials: K
authors.lastname: Panyakhamlerd
authors.forename: Unnop
authors.initials: U
authors.lastname: Jaisamrarn
authors.forename: Kitirat
authors.initials: K
authors.lastname: Techatraisak
authors.forename: Nuntana
authors.initials: N
authors.lastname: Morakote
authors.forename: Charnchai
authors.initials: C
authors.lastname: Suchartwatnachai
authors.forename: Worapong
authors.initials: W
authors.lastname: Kongmephol
authors.forename: Nimit
authors.initials: N
authors.lastname: Taechakraichana
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000736:Androstenes / Q000009:adverse effects / Q000627:therapeutic use*; D044466:Asian People; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000009:adverse effects / Q000627:therapeutic use*; D004967:Estrogens / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D020249:Hormone Replacement Therapy; D019584:Hot Flashes / Q000188:drug therapy; D006801:Humans; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D017698:Postmenopause / Q000187:drug effects*; D013785:Thailand; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000736:Androstenes; D004967:Estrogens; D000451:Mineralocorticoid Receptor Antagonists; D004958:Estradiol; C035144:drospirenone